Plain-English translation of NCT04515836 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Mesothelioma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called in patients with mesothelioma — a serious cancer often linked to asbestos exposure — who have specific changes in their cancer's DNA. The medication works by targeting these genetic changes to help slow or shrink tumors. Researchers want to see if this treatment can help patients whose mesothelioma has certain genetic features that make it a good match for this approach.
Mesothelioma is a difficult cancer to treat, and many patients need better options beyond standard chemotherapy. This trial exists because recent discoveries show that some mesotheliomas have specific genetic mutations that this medication is designed to attack, offering hope for a more targeted treatment approach.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth in 28-day cycles. You'll visit the clinic on day 1 and day 15 of your first cycle, then every 4 weeks on day 1 of each subsequent cycle while you're receiving treatment. At these visits, doctors will monitor your health, check your blood work, and use CT scans to see if your tumor is responding to the medication. The study involves genetic testing of your tumor and normal cells to confirm you're eligible and to help researchers understand how the treatment works.
AI-generated summary from trial data · Aug 24, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
University of Chicago
Collaborators
AstraZeneca
Enrollment target
~56 participants
Started
February 2021
Primary completion
April 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Hedy L Kindler, MD
University of Chicago
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.